Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals

Designing a Rational Bispecific ADC for New Therapeutic Opportunity Against Aggressive B-Cell Lymphoma

By | 8 June 2026

Contextualizing Double Hit Lymphoma (DHL) as a rare and highly aggressive B-cell lymphoma with rapid disease progression, treatment resistance, and poor patient survival outcomes
Evaluating studies indicating CDK9 as a key driver of the aggressive and therapy-resistant behavior of DHL
Developing a bispecific ADC to target CDK9 to selectively target DHL cells and mitigate off-tumor, on-target toxicity associated with past clinical failures